Literature DB >> 16765395

Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated falciparum malaria in Koumantou, Mali.

Xavier de Radiguès1, Kandian I Diallo, Mouctar Diallo, Paul Akisa Ngwakum, Hamma Maiga, Abdoulaye Djimdé, Massambou Sacko, Ogobara Doumbo, Jean-Paul Guthmann.   

Abstract

We report the results of an in vivo antimalarial efficacy study with chloroquine (CQ) and sulfadoxine/pyrimethamine (SP) conducted between 2003 and 2004 in Koumantou, southern Mali. A total of 244 children were included in the study; 210 children were followed-up for 28 days according to WHO recommendations, with PCR genotyping to distinguish late recrudescence from re-infection. Global failure proportions at Day 14, without taking into account re-infections, were 44.2% (95% CI 34.9-53.5%) in the CQ group and 2.0% (95% CI 0.0-4.8%) in the SP group. PCR-adjusted failure proportions at Day 28 were even higher in the CQ group (90.5% (95/105), 95% CI 84.8-96.2%) and relatively low in the SP group (7.0% (7/100), 95% CI 1.9-12.1%). These results show that CQ is no longer efficacious in Koumantou. The use of SP in monotherapy is likely to compromise its efficacy. We recommend the use of artemisinin-based combination therapy as first-line treatment for uncomplicated Plasmodium falciparum malaria in Koumantou.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16765395     DOI: 10.1016/j.trstmh.2006.03.004

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

1.  Operational research in non-governmental organisations: necessity or luxury?

Authors:  Rony Zachariah; Bertrand Draquez
Journal:  Public Health Action       Date:  2012-06-21

2.  Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali.

Authors:  Hamma Maiga; Abdoulaye A Djimde; Abdoul H Beavogui; Ousmane Toure; Mamadou Tekete; Cheick Papa O Sangare; Antoine Dara; Zoumana I Traore; Oumar B Traore; Souleymane Dama; Christelle N'Dong; Hamidou Niangaly; Nouhoum Diallo; Demba Dembele; Issaka Sagara; Ogobara K Doumbo
Journal:  Malar J       Date:  2015-02-07       Impact factor: 2.979

3.  Low Prevalence of Pfcrt Resistance Alleles among Patients with Uncomplicated Falciparum Malaria in Niger Six Years after Chloroquine Withdrawal.

Authors:  Adamou Salissou; Halima Zamanka; Brigitte Biyghe Binze; Taiana Rivière; Magalie Tichit; Maman Laminou Ibrahim; Thierry Fandeur
Journal:  Malar Res Treat       Date:  2014-11-23

4.  Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data.

Authors: 
Journal:  BMC Med       Date:  2022-03-07       Impact factor: 8.775

5.  Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali.

Authors:  Kassoum Kayentao; Hamma Maiga; Robert D Newman; Meredith L McMorrow; Annett Hoppe; Oumar Yattara; Hamidou Traore; Younoussou Kone; Etienne A Guirou; Renion Saye; Boubacar Traore; Abdoulaye Djimde; Ogobara K Doumbo
Journal:  Malar J       Date:  2009-01-07       Impact factor: 2.979

6.  The role of community health workers in improving child health programmes in Mali.

Authors:  Freddy Perez; Hamady Ba; Sayed G Dastagire; Mathias Altmann
Journal:  BMC Int Health Hum Rights       Date:  2009-11-10

7.  Efficacy of Pyrimethamine/Sulfadoxine versus Chloroquine for the Treatment of Uncomplicated Falciparum Malaria in Children Aged Under 5 Years.

Authors:  W Zheng; H Jiang; Z Xiong; Z Jiang; H Chen
Journal:  Iran J Parasitol       Date:  2013-01       Impact factor: 1.012

8.  Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Médecins Sans Frontières.

Authors:  Jean-Paul Guthmann; Francesco Checchi; Ingrid van den Broek; Suna Balkan; Michel van Herp; Eric Comte; Oscar Bernal; Jean-Marie Kindermans; Sarah Venis; Dominique Legros; Philippe J Guerin
Journal:  PLoS Med       Date:  2008-08-05       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.